Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands

BMC Health Services Research

Volumn 10, Issue , 2010, Pages

  Van Lier, Alies ^a   Van Hoek, Albert Jan ^b   Opstelten, Wim ^c   Boot, Hein J ^a   De Melker, Hester E ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

VARICELLA ZOSTER VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG CONTRAINDICATION; ECONOMICS; FEMALE; HERPES ZOSTER; HUMAN; INFANT; MALE; MIDDLE AGED; NETHERLANDS; ORGANIZATION AND MANAGEMENT; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; IMMUNIZATION PROGRAMS; INFANT; MALE; MIDDLE AGED; NETHERLANDS; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955490416     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-10-237     Document Type: Article

References (39)

1. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). R Harpaz IR Ortega-Sanchez JF Seward, MMWR Recomm Rep 2008 57 1 30 18528318
2. European Public Assessment Report (EPAR) ZOSTAVAX. European Medicines Agency, London, UK: European Medicines Agency 2006 Report No.: EMEA/H/C/674
3. Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs. TG Kimman HJ Boot GA Berbers PE Vermeer-de Bondt G Ardine de Wit HE de Melker, Vaccine 2006 24 4769 78 10.1016/j.vaccine.2006.03.022 16616803
4. Vaccines. SA Plotkin WA Orenstein PA Offit, Philadelphia: Saunders Elsevier 2008
5. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. MN Oxman MJ Levin GR Johnson KE Schmader SE Straus LD Gelb RD Arbeit MS Simberkoff AA Gershon LE Davis A Weinberg KD Boardman HM Williams JH Zhang PN Peduzzi CE Beisel VA Morrison JC Guatelli PA Brooks CA Kauffman CT Pachucki KM Neuzil RF Betts PF Wright MR Griffin P Brunell NE Soto AR Marques SK Keay RP Goodman DJ Cotton JW Gnann Jr J Loutit M Holodniy WA Keitel GE Crawford SS Yeh Z Lobo JF Toney RN Greenberg PM Keller R Harbecke AR Hayward MR Irwin TC Kyriakides CY Chan IS Chan WW Wang PW Annunziato JL Silber, N Engl J Med 2005 352 2271 84 10.1056/NEJMoa051016 15930418
6. Monitoring national influenza prevention programme 2008 (in Dutch). M Tacken J Mulder H van den Hoogen W Tiersma J Donkers R Verheij J Braspenning, Nijmegen: LINH (IQ Healthcare) 2009
7. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. B Kerzner AV Murray E Cheng R Ifle PR Harvey M Tomlinson JL Barben K Rarrick JE Stek MO Chung FP Schodel WW Wang J Xu IS Chan JL Silber K Schlienger, J Am Geriatr Soc 2007 55 1499 507 10.1111/j.1532-5415.2007.01397.x 17908055
8. Determinants of non-compliance with herpes zoster vaccination in the community-dwelling elderly. W Opstelten GA van Essen E Hak, Vaccine 2009 27 192 6 18996427
9. Importance of patients' perceptions and general practitioners' recommendations in understanding missed opportunities for immunisations in Swiss adults. PA Bovier E Chamot M Bouvier Gallacchi L Loutan, Vaccine 2001 19 4760 7 10.1016/S0264-410X(01)00223-7 11535327
10. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. PJ Lu GL Euler AO Jumaan R Harpaz, Vaccine 2009 27 882 7 10.1016/j.vaccine.2008.11.077 19071175
11. Patient awareness of herpes zoster: the Global Herpes Zoster Survey - a preliminary report. RW Johnson, Herpes 2006 13 40 41A
12. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. H De Melker G Berbers S Hahne H Rumke S van den Hof A de Wit H Boot, Vaccine 2006 24 3946 52 10.1016/j.vaccine.2006.02.017 16564115
13. Prevention of herpes zoster and its painful and debilitating complications. R Johnson J McElhaney B Pedalino M Levin, Int J Infect Dis 2007 11 Suppl 2 43 8 10.1016/S1201-9712(07)60021-6 18162246
14. Distribution of varicella-zoster virus (VZV) wild-type genotypes in northern and southern Europe: evidence for high conservation of circulating genotypes. VN Loparev EN Rubtcova V Bostik V Tzaneva A Sauerbrei A Robo E Sattler-Dornbacher I Hanovcova V Stepanova M Splino V Eremin M Koskiniemi OE Vankova DS Schmid, Virology 2009 383 216 25 10.1016/j.virol.2008.10.026 19019403
15. Comparative analyses of the 9 glycoprotein genes found in wild-type and vaccine strains of varicella-zoster virus. J Storlie L Maresova W Jackson C Grose, J Infect Dis 2008 197 Suppl 2 49 53 10.1086/522127 18419408
16. Assessing the introduction of universal varicella vaccination in the Netherlands. HJ Boot HE de Melker EA Stolk GA de Wit TG Kimman, Vaccine 2006 24 6288 99 10.1016/j.vaccine.2006.05.071 16790302
17. Development of varicella vaccine. M Takahashi Y Asano H Kamiya K Baba T Ozaki T Otsuka K Yamanishi, J Infect Dis 2008 197 Suppl 2 41 4 10.1086/522132 18419406
18. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. K Schmader JW Gnann Jr CP Watson, J Infect Dis 2008 197 Suppl 2 207 15 10.1086/522152 18419399
19. Gender as an independent risk factor for herpes zoster: a population-based prospective study. W Opstelten GA Van Essen F Schellevis TJ Verheij KG Moons, Ann Epidemiol 2006 16 692 5 10.1016/j.annepidem.2005.12.002 16516488
20. Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. W Opstelten NP Zuithoff GA van Essen AM van Loon AJ van Wijck CJ Kalkman TJ Verheij KG Moons, Pain 2007 132 Suppl 1 52 9 10.1016/j.pain.2007.02.004 17379412
21. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. M Brisson NJ Gay WJ Edmunds NJ Andrews, Vaccine 2002 20 2500 7 10.1016/S0264-410X(02)00180-9 12057605
22. Incidence of herpes zoster, before and after varicella-vaccination- associated decreases in the incidence of varicella, 1992-2002. AO Jumaan O Yu LA Jackson K Bohlke K Galil JF Seward, J Infect Dis 2005 191 2002 7 10.1086/430325 15897984
23. Incidence of herpes zoster, 1997-2002. JP Mullooly K Riedlinger C Chun S Weinmann H Houston, Epidemiol Infect 2005 133 245 53 10.1017/S095026880400281X 15816149
24. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. BP Yawn P Saddier PC Wollan JL St Sauver MJ Kurland LS Sy, Mayo Clin Proc 2007 82 1341 9 10.4065/82.11.1341 17976353
25. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. WK Yih DR Brooks SM Lett AO Jumaan Z Zhang KM Clements JF Seward, BMC Public Health 2005 5 68 10.1186/1471-2458-5-68 15960856
26. Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States. MS Patel A Gebremariam MM Davis, Infect Control Hosp Epidemiol 2008 29 1157 63 10.1086/591975 18999945
27. Netherlands Information Network of General Practice (LINH): Facts and figures on GP care in the Netherlands. RA Verheij CE van Dijk H Abrahamse R Davids H Van den Hoogen J Braspenning T Van Althuis, Utrecht/Nijmegen: NIVEL/WOK 2008
28. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. AJ van Hoek N Gay A Melegaro W Opstelten WJ Edmunds, Vaccine 2009 27 1454 67 10.1016/j.vaccine.2008.12.024 19135492
29. Dutch National Medical Register. Prismant, Utrecht: Prismant 2000
30. Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia. M Brisson JM Pellissier MJ Levin, Clin Infect Dis 2007 45 1527 9 10.1086/523011 17990240
31. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. AJ van Wijck W Opstelten KG Moons GA van Essen RJ Stolker CJ Kalkman TJ Verheij, Lancet 2006 367 219 24 10.1016/S0140-6736(06)68032-X 16427490
32. The burden of Herpes Zoster: a prospective population based study. FT Scott RW Johnson M Leedham-Green E Davies WJ Edmunds J Breuer, Vaccine 2006 24 1308 14 10.1016/j.vaccine.2005.09.026 16352376
33. Increased Risk of Stroke After a Herpes Zoster Attack: A Population-Based Follow-Up Study. JH Kang JD Ho YH Chen HC Lin, Stroke 2009 40 3443 8 10.1161/STROKEAHA.109.562017 19815828
34. Criteria for inclusion of vaccinations in public programmes. H Houweling M Verweij EJ Ruitenberg National Immunisation Programme Review Committee of the Health Council of the Netherlands, Vaccine 2010 28 2924 31 10.1016/j.vaccine. 2010.02.021 20189486
35. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. J Hornberger K Robertus, Ann Intern Med 2006 145 317 25 16954357
36. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. MB Rothberg A Virapongse KJ Smith, Clin Infect Dis 2007 44 1280 8 10.1086/514342 17443464
37. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. JM Pellissier M Brisson MJ Levin, Vaccine 2007 25 8326 37 10.1016/j.vaccine.2007.09.066 17980938
38. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. M Brisson JM Pellissier S Camden C Quach P De Wals, Hum Vaccin 2010 4 238 245 18382137
39. Cost effectiveness of herpes zoster vaccine in Canada. M Najafzadeh CA Marra E Galanis DM Patrick, Pharmacoeconomics 2009 27 991 1004 10.2165/11314010-000000000-00000 19908924